Exact Sciences makes acquisition to support blood-based cancer test development — 4 insights

Exact Sciences acquired sample preservation technology developer Biomatrica to support efforts to develop a blood-based cancer detection test.

Advertisement

Here’s what you should know:

1. The companies aren’t disclosing financial terms of the deal.

2. Biomatrica will become a wholly-owned Exact Sciences subsidiary but continue to operate out of San Diego.

3. Biomatrica has eight U.S. utility patents, one U.S. design patent and 36 foreign patents. The company has four patents pending in the U.S.

4. Exact Sciences Chairman and CEO Kevin Conroy said, “To detect cancer at its earliest stages, you need the right team backed by the highest-quality science, data and materials. Biomatrica’s preservation chemistry ensures the reliability of results, even when blood and other biological samples undergo the stresses of shipping and storage.”

More articles on gastroenterology:
The 3 reasons why physicians often lack leadership training
82 benchmarks to know on procedure, case volume
The Joint Commission taps new co-directors of the standards interpretation group: 3 insights

At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.

Register to Attend Webinar

Building a High-Performance Cardiac PET Program: What Health Systems Should Consider

Thursday, July 30
12:00 PM - 1:00 PM CDT

Presenters: Rupa Sanghani, MD, FACC, FASNC, Rush University Medical CenterBrendon Loiselle, CDL Nuclear Technologies

Advertisement

Next Up in GI & Endoscopy

Advertisement

Comments are closed.